Alicia J. Hager
Known title: Chief Legal OfficerCIK: 0001553354
Associated companies
Transaction History
| NKTX | ▼ Sell | Open Market | 9,584 | $21K | 1/15/2025 | View on chart |
| NKTX | ▲ Buy | Grant | 52,500 | $0 | 1/3/2025 | View on chart |
| NKTX | ▼ Sell | Open Market | 3,396 | $27K | 7/16/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 727 | $4K | 6/18/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 4,554 | $40K | 1/16/2024 | View on chart |
| NKTX | ▲ Buy | Grant | 56,000 | $0 | 1/4/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 701 | $3K | 6/20/2023 | View on chart |
| NKTX | ▼ Sell | Open Market | 1,103 | $6K | 1/17/2023 | View on chart |
| NKTX | ▲ Buy | Grant | 37,500 | $0 | 1/13/2023 | View on chart |
| NKTX | ▲ Buy | Grant | 8,000 | $0 | 6/17/2022 | View on chart |
| NKTX | ▲ Buy | Grant | 12,800 | $0 | 1/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress
Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress. Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.